Skip to content
Elios Vision logo

Elios Vision, Inc. announces medical advisory board

Elios Vision, Inc. today announced the creation of its medical advisory board. The group of internationally-recognized ophthalmic and glaucoma key opinion leaders will collaborate with Elios Vision to bring the company’s ELIOS ELT device, which has already received a CE mark in Europe, into clinical trial in the United States and to expand its international use. The ELIOS ELT device is a specialized excimer laser system used for microinvasive glaucoma surgery (MIGS) to lower eye pressure in patients with glaucoma.

Elios Vision recently announced that in the largest published study to date on ELT, the ExTra ELT procedure plus cataract surgery was superior to ab interno trabeculectomy with the trabectome plus cataract surgery in survival analysis.

“We are excited to bring together this group of world-renowned glaucoma specialists,” said Elliot Friedman, Chief Executive Officer of Elios Vision. “Their expertise and leadership in the ophthalmology field will help propel us closer to clinical trial of ELIOS ELT and regulatory approval in the U.S.,” he added.

Members of the medical advisory board include:

  • Iqbal Ike K. Ahmed, MD: Assistant Professor, University of Toronto
  • Richard A. Lewis, MD: Co-Founder of Sacramento Eye Consultants; Past President, American Glaucoma Society and American Society of Cataract and Refractive Surgeons
  • Antonio Fea, MD, PhD: Head of the Glaucoma Unit, University of Torino
  • Thomas W. Samuelson, MD: Adjunct Professor of Ophthalmology, University of Minnesota; Glaucoma and Anterior Segment Surgery, Minnesota Eye Consultants
  • Marc Töteberg-Harms, MD, FEBO: Senior Attending Surgeon, Director of Glaucoma Service, University Hospital Zurich
  • Thomas Neuhann, MD: Founder and Medical Director, MVZ Prof. Neuhann; Chief, Eye Dept., Red Cross Clinic, Munich
  • Nathan Radcliffe, MD: Ophthalmic Surgeon, Microincisional Glaucoma Surgery Center; Associate Clinical Professor, New York Eye & Ear Infirmary at Mount Sinai
  • Antonio Moreno Valladares, MD, PhD: Ophthalmic Surgeon, University Hospital of Albacete

Dr. Ike Ahmed stated, “Using the precision and microinvasive qualities of excimer laser technology, ELT holds promise as a microinvasive glaucoma surgery (MIGS) procedure. Currently available evidence shows an intraocular pressure (IOP)-lowering effect from ELT alone or in combination with cataract surgery with encouraging results across different studies and patient populations and a favorable safety profile.”

“ELT has several potential advantages, including that it does not rely on a permanent device inserted into the anterior chamber or destroy the outflow pathway as with trabectome and some goniotomies,” commented Dr. Fea.

Dr. Valladares added, “ELT is a non-implant-dependent MIGS technique that offers a wide range of advantages over other trabecular techniques, with a high safety profile, a short learning curve and a proven long-term efficacy, which is easily combinable with cataract surgery and which does not compromise the success of future filtering surgeries.”

Share This Story

Latest News

Video: Combined Phacoemulsification and ELIOS for Medication Reduction

Dr. Antonio Moreno-Valladares discusses a recent study of medication reduction outcomes for the ELIOS procedure combined with phacoemulsification.

Elios Vision announces collaboration with the International Glaucoma Surgical Registry

Elios Vision will be collaborating with the ISGR, an open-access tool which enables surgeons to compare outcomes with other centres.
Elios Vision logo

Elios Vision achieves three new pipeline milestones

Elios announced enrollment completion in their U.S. pivotal trial, the expansion of the U.S. pre-launch team, and continued commercial uptake in Europe.

Join Our Email List

Stay up-to-date on the next generation of glaucoma treatment. Subscribe to receive educational and promotional information from Elios Vision.

Email Signup

Site for Healthcare Professionals Only

You are about to access Elios Vision’s online platform for healthcare professionals outside of the United States. This platform is intended to provide general product information for education and illustration purposes. It is not intended to provide information to the general public or medical advice.

As product information, availability, indication, and trade names may vary from country to country, the content of this site may not be fully in-line with the approved or cleared product information in the country you are accessing from. Unless stated otherwise for specific product or event pages, the content on this site is based on the regulatory and legal principles applicable to the United Kingdom.

By clicking “Proceed,” I confirm that:

  • I understand that this platform is directed to Healthcare Professionals only and that I am a licensed Healthcare Professional.
  • I have read and agree to Elios Vision’s terms and conditions and privacy policy.